Share information
251.90 €
+1.45 %
03/06/2026 17:35
+1.45 %
Open
High
Low
Volume
246.00 €
252.50 €
244.20 €
187,603
Latest News
03-Jun-2026
BIMZELX[®](bimekizumab) data at EULAR 2026 show early and sustained inflammation control can improve patient reported outcomes and limit disease progression in PsA and axSpA
02-Jun-2026
UCB presents research at EUROMIT 2026 highlighting burden of care, need for earlier diagnosis, and impact of pyrimidine nucleoside therapy on people living with TK2d
02-Jun-2026
UCB completes acquisition of Neurona Therapeutics, advancing its leadership as innovator in epilepsy through regenerative science
01-Jun-2026
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus